Phase 3 study of MK4280A (coformulated favezelimab and pembrolizumab) versus standard of care in previously treated PD-L1epositive metastatic colorectal cancer (mCRC)

T. Kim; J. Taieb; M. Passhak; T. Kim; S. Kim; R. Geva; E. Hofsli; G. Perl; S. Yalcin; A. Hubert; B. Somer; Z. Wong; A. Wang; P. Leconte; D. Fogelman; V. Heinemann

doi:10.1016/j.annonc.2022.04.171

Phase 3 study of MK4280A (coformulated favezelimab and pembrolizumab) versus standard of care in previously treated PD-L1epositive metastatic colorectal cancer (mCRC)

T. Kim
, J. Taieb
, M. Passhak
, T. Kim
, S. Kim
, R. Geva
, E. Hofsli
, G. Perl
, S. Yalcin
, A. Hubert
, B. Somer
, Z. Wong
, A. Wang
, P. Leconte
, D. Fogelman
, V. Heinemann

Araştırma sonucu: Dergiye katkı › Toplantı Özeti › bilirkişi

Orijinal dil	İngilizce
Sayfa (başlangıç-bitiş)	S277-S277
Sayfa sayısı	1
Dergi	Annals of Oncology
Hacim	33
DOI'lar	https://doi.org/10.1016/j.annonc.2022.04.171
Yayın durumu	Yayınlandı - Haz 2022
Etkinlik	ESMO 24th World Congress on Gastrointestinal Cancer - Barcelona, !!Spain Süre: 29 Haz 2022 → 2 Tem 2022

BM SKH

Bu sonuç, aşağıdaki Sürdürülebilir Kalkınma Hedefine/Hedeflerine katkıda bulunur

SKH 3 Sağlık ve Kaliteli Yaşam

Belgeye Erişim

10.1016/j.annonc.2022.04.171

Diger dosyalar ve linkler

View record in Web of Science

Bundan alıntı yap

Kim, T., Taieb, J., Passhak, M., Kim, T., Kim, S., Geva, R., Hofsli, E., Perl, G., Yalcin, S., Hubert, A., Somer, B., Wong, Z., Wang, A., Leconte, P., Fogelman, D., & Heinemann, V. (2022). Phase 3 study of MK4280A (coformulated favezelimab and pembrolizumab) versus standard of care in previously treated PD-L1epositive metastatic colorectal cancer (mCRC). Annals of Oncology, 33, S277-S277. https://doi.org/10.1016/j.annonc.2022.04.171

@article{dedcf13e3f15477da6fda4316cceb73f,

title = "Phase 3 study of MK4280A (coformulated favezelimab and pembrolizumab) versus standard of care in previously treated PD-L1epositive metastatic colorectal cancer (mCRC)",

author = "T. Kim and J. Taieb and M. Passhak and T. Kim and S. Kim and R. Geva and E. Hofsli and G. Perl and S. Yalcin and A. Hubert and B. Somer and Z. Wong and A. Wang and P. Leconte and D. Fogelman and V. Heinemann",

year = "2022",

month = jun,

doi = "10.1016/j.annonc.2022.04.171",

language = "English",

volume = "33",

pages = "S277--S277",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd",

note = "ESMO 24th World Congress on Gastrointestinal Cancer ; Conference date: 29-06-2022 Through 02-07-2022",

}

Kim, T, Taieb, J, Passhak, M, Kim, T, Kim, S, Geva, R, Hofsli, E, Perl, G, Yalcin, S, Hubert, A, Somer, B, Wong, Z, Wang, A, Leconte, P, Fogelman, D & Heinemann, V 2022, 'Phase 3 study of MK4280A (coformulated favezelimab and pembrolizumab) versus standard of care in previously treated PD-L1epositive metastatic colorectal cancer (mCRC)', Annals of Oncology, hac. 33, pp. S277-S277. https://doi.org/10.1016/j.annonc.2022.04.171

TY - JOUR

T1 - Phase 3 study of MK4280A (coformulated favezelimab and pembrolizumab) versus standard of care in previously treated PD-L1epositive metastatic colorectal cancer (mCRC)

AU - Kim, T.

AU - Taieb, J.

AU - Passhak, M.

AU - Kim, T.

AU - Kim, S.

AU - Geva, R.

AU - Hofsli, E.

AU - Perl, G.

AU - Yalcin, S.

AU - Hubert, A.

AU - Somer, B.

AU - Wong, Z.

AU - Wang, A.

AU - Leconte, P.

AU - Fogelman, D.

AU - Heinemann, V.

PY - 2022/6

Y1 - 2022/6

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=performanshacettepe&SrcAuth=WosAPI&KeyUT=WOS:000823826500094&DestLinkType=FullRecord&DestApp=WOS_CPL

U2 - 10.1016/j.annonc.2022.04.171

DO - 10.1016/j.annonc.2022.04.171

M3 - Meeting Abstract

SN - 0923-7534

VL - 33

SP - S277-S277

JO - Annals of Oncology

JF - Annals of Oncology

T2 - ESMO 24th World Congress on Gastrointestinal Cancer

Y2 - 29 June 2022 through 2 July 2022

ER -